It appears that vaccine manufacturers are ever more impatient to reap high profits from new vaccines — especially since they have entered into “public-private” partnerships with governments. Increasingly, government officials oblige this greed-infected industry with laws mandating new vaccines. And public health authorities around the globe have become marketing auxiliaries for vaccine manufacturers. A report…

Read More

Corporate-influenced medicine favors the one-size-fits-all paradigm of care, a paradigm that disregards individual human differences, circumstances, and needs. Why? I believe the answer is simple; because the one-size-fits-all is the cheapest most profitable paradigm to get the largest number of customers. “A key drive for unreliable research: the greater the financial interest in a given…

Read More
Meryl Nass, MD

Whereas government agencies in Canada, Australia European countries set limits on the cost of prescription drugs, in the United States, thanks to a laissez faire government pass, pharmaceutical companies are encouraged to set prescription drug prices however high they wish without any limits. This is an unsustainable public policy. (Read more at Health Affairs.org) An…

Read More

1967-1968: Grünenthal executives were put on trial in Aachen, Germany The indictment charged the company with intent to commit bodily harm and involuntary manslaughter.  The central defendant was Dr. Heinrich Mückter, an indicted Nazi war criminal, who was the company’s chief scientist and head of research. Mückter was credited with the development of thalidomide and…

Read More

“How Men Who Blighted Lives of thousands Evaded Justice.” The post-WWII horror story of thalidomide begins in the picture-book town of Stolberg, near Aachen, in western Germany, with the establishment of Chemie Grünenthal, a Wirtz family-owned pharmaceutical company. After WWII, Nazi scientists stared down their pasts and searched for career opportunities; they gravitated toward fiercely competitive…

Read More
teenscreen-not-lab-rat.jpg

   The following announcement was posted on TeenScreen’s website (November 15, 2012):  "Important Announcement for Schools & Communities:  We are sorry to inform you that the TeenScreen National Center will be winding down its program at the end of this year. Accordingly, we will no longer train or register new programs."   http://www.teenscreen.org/ No explanation was…

Read More

The decision to suspend the trial is viewed as highly questionable, raising disturbing questions about the role that marketing played–especially in light of the fact that Zytiga’s patent is due to expire in 2017. 

Read More

The FDA granted market exclusivity to KV for an old drug that had been available from special pharmacies that custom-compound treatments not approved by the FDA, for $20 a shot. By granting KV market exclusivity, women could no longer obtain the drug, Makena, at a reasonable price– KV set the price at $1,500 a shot.

Read More